Skip to main content
. 2017 Mar 14;140(5):1420–1436. doi: 10.1093/brain/awx044

Figure 5.

Figure 5

Insulin resistance in PLP-SYN mice is reversed by exendin-4 treatment. (A) Representative image of IRS-1pS307 protein levels in the striatum of PLP-SYN mice and wild-type littermates. (B) Significant increase in striatal IRS-1pS307 protein levels in PLP-SYN mice (n = 7) compared to wild-type (WT) littermates (n = 7). (C) Representative image of striatal IRS-pS612 protein expression levels in the striatum of PLP-SYN mice and wild-type littermates. (D) No difference was observed in IRS-1pS612 protein levels between groups. (E and G) Representative images of IRS-1pS307 and IRS-1pS612 protein expression in the striatum of PLP-SYN mice treated with placebo (n = 9), 3.5 pmol/kg/min (n = 9) or 8.75 pmol/kg/min exendin-4 (n = 7). (F and H) Significant decrease in IRS-1pS307 and IRS-1pS612 protein expression in the 8.75 pmol/kg/min exendin-4 treated group (n = 7) compared to placebo PLP-SYN mice (n = 9). A t-test was used to compare striatal IRS-1pS307 and IRS-1pS612 protein expression levels between PLP-SYN and wild-type littermates. A one-way ANOVA was applied to compare treatment effects of exendin-4 between groups, followed by post hoc Holm-Sidak tests for multiple comparisons if appropriate. If data were not normally distributed, an ANOVA on ranks was performed instead, followed by Dunn’s multiple comparisons when appropriate. Values are mean ± SEM. *P < 0.05 versus placebo PLP-SYN, **P < 0.01 versus placebo PLP-SYN. A.U. = arbitrary units.